Brain metastases as preventive and therapeutic targets

Nature Reviews Cancer

Volumn 11, Issue 5, 2011, Pages 352-363

  Steeg, Patricia S ^a   Camphausen, Kevin A ^b   Smith, Quentin R ^c  

^a Laboratory of Molecular Pharmacology   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CAPECITABINE; DASATINIB; ERLOTINIB; IMATINIB; JNJ 28871063; LAPATINIB; PAZOPANIB; RADIOSENSITIZING AGENT; SAGIPILONE; SORAFENIB; SUNITINIB; TANDUTINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VORINOSTAT; WP 1066;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CELLULAR DISTRIBUTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG UPTAKE; HUMAN; MENINGEAL METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; RADIOBIOLOGY; REVIEW; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; HUMANS;

EID: 79955475531     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3053     Document Type: Review

References (142)

1. Yamanaka, R. Medical management of brain metastases from lung cancer (Review). Oncol. Rep. 22, 1269-1276 (2009).
2. Oh, Y. et al. Number of metastatic sites is a strong predictor of survival in paitents with nonsmall cell lung cancer with or without brain metastases. Cancer 115, 2930-2938 (2009).
3. Lin, N., Bellon, J. & Winer, E. CNS metastases in breast cancer. J.Clin. Oncol. 22, 3608-3617 (2004). (Pubitemid 41103668)
4. Lin, N.U. & Winer, E.P. Brain metastases: the HER2 paradigm. Clin. Cancer Res. 13, 1648-1655 (2007). (Pubitemid 46952930)
5. Weil, R., Palmieri, D., Bronder, J., Stark, A. & Steeg, P. Breast cancer metastasis to the central nervous system. Am. J.Pathol. 167, 913-920 (2005). (Pubitemid 41416243)
6. Bendell, J. et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97, 2972-2977 (2003). (Pubitemid 36676250)
7. Lin, N. et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. High incidence of central nervous system metastases. Cancer 113, 2638-2645 (2008).
8. Tsukada, Y., Fouad, A., Pickren, J.W. & Lane, W.W. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52, 2349-2354 (1983). (Pubitemid 14205961)
9. Miller, K. et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann. Oncol. 14, 1072-1077 (2003). (Pubitemid 36950171)
10. McWilliams, R. et al. Melanoma-induced brain metastases. Expert Rev. Anticancer Ther. 8, 743-755 (2008).
11. Mattieu, A. et al. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice. Cancer 101, 1908-1918 (2004).
12. Zhang, Z., Hatori, T. & Nonaka, H. An experimental model of brain metastasis of lung carcinoma. Neuropathology 28, 24-28 (2008).
13. Kienast, Y. et al. Real-time imaging reveals the single steps in brain metastasis formation. Nature Med. 16, 116-122 (2010).
14. Yoneda, T., Williams, P., Hiraga, T., Niewolna, M. & Nishimura, R. A bone seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking cloe invivo and invitro. J.Bone Miner. Res. 16, 1486-1495 (2001). (Pubitemid 32675200)
15. Lockman, P. et al. Heterogeneous blood-brain barrier permeability determines drug efficacy in mouse brain metastases of breast cancer. Clin. Cancer Res. 16, 5662-5678 (2010).
16. Gril, B. et al. Pazopanib reveals a role for tumor cell B-Raf in the prevention of breast cancer brain metastasis. Clin. Cancer Res. 17, 142-153 (2010).
17. Bos, P. et al. Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1010 (2009).
18. Price, J.E., Polyzos, A., Zhang, R.D. & Daniels, L.M. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 50, 717-721 (1990). (Pubitemid 20054204)
19. Rye, P. et al. Brain metastasis model in athymic nude mice using a novel MUC1-secreting human breast-cancer cell line, MA11. Int. J.Cancer 68, 682-687 (1996). (Pubitemid 26414532)
20. Carbonell, W., Ansorge, O., Sibson, N. & Muschel, R. The vascular basement membrane as "soil" in brain metastasis. PLoS ONE 4, e5857 (2009).
21. Leenders, W. et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel cooption. Clin. Cancer Res. 10, 6222-6230 (2004). (Pubitemid 39287530)
22. Cranmer, L.D., Trevor, K.T., Bandlamuri, S. & Hersh, E.M. Rodent models of brain metastasis in melanoma. Melanoma Res. 15, 325-356 (2005). (Pubitemid 41558944)
23. Zhang, C., Zhang, F., Tsan, R. & Fidler, I. Transforming growth factor β2 is a molecular determinant for site specific melanoma metastasis in the brain. Cancer Res. 69, 828-835 (2009).
24. Huang, F.-J. et al. Molecular basis of the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res. 68, 9634-9642 (2008).
25. Yin, J. et al. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin. Exp. Metastasis 26, 403-414 (2009).
26. Kruger, A. et al. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 16, 2419-2423 (1998). (Pubitemid 28226891)
27. Maillard, C. et al. Reduction of brain metastases in plasminogen activator inhibitor-1 deficient mice with transgenic ocular tumors. Carcinogenesis 29, 2236-2242 (2008).
28. Cruz-Munoz, W., Man, S., Xu, P. & Kerbel, R. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res. 68, 4500-4505 (2008).
29. Fitzgerald, D. et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin. Exp. Metast. 25, 799-810 (2008).
30. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1, 99-101 (1889).
31. Lorger, M. & Felding-Habermann, B. Capturing changes in the brain microenvironment during intial steps of breast cancer brain metastasis. Am. J.Pathol. 176, 2958-2971 (2010).
32. Zhang, M. & Olsson, Y. Hematogenous metastases of the human brain - characteristics of peritumoral brain changes: a review. J.Neurooncol. 35, 81-89 (1997). (Pubitemid 27361849)
33. Seike, T. et al. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin. Exp. Metastasis 28, 13-25 (2011).
34. Lin, Q. et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 12, 748-754 (2010).
35. Pukrop, R. et al. Microglia promote the colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia 58, 1477-1489 (2010).
36. Salgado, K., Toscani, N., Silva, L., Hilbig, A. & Barbosa-Coutinho, L. Immunoexpression of endoglin in brain metastasis secondary to malignant melanoma: evaluation of angiogenesis and comparison with brain metastasis secondary to breast and lung carcinomas. Clin. Exp. Metastasis 24, 403-410 (2007). (Pubitemid 47367682)
37. Leenders, W. et al. Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI. Int. J.Cancer 105, 437-443 (2003). (Pubitemid 36578545)
38. Kim, L., Huang, S., Lu, W., Lev, D.C. & Price, J. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin. Exp. Metastasis 21, 107-118 (2004). (Pubitemid 38988084)
39. Heyn, C. et al. Invivo magnetic resonance imaging of single cells in mouse brains with optical validation. Magn. Reson. Med. 55, 23-29 (2006). (Pubitemid 43062924)
40. Silva, L.D. et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res. 12, 1-13 (2010).
41. Sun, M. et al. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin. Cancer Res. 15, 4829-4837 (2009).
42. Koo, J. & Kim, S. EGFR and HER-2 status of non-small cell lung cancer brain metastasis and corresponding primary tumor. Neoplasma 58, 27-34 (2011).
43. Milas, I. et al. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases. Clin. Cancer Res. 9, 1070-1076 (2003). (Pubitemid 36323713)
44. Gaedcke, J. et al. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod. Pathol. 20, 864-870 (2007). (Pubitemid 47077270)
45. Wu, P.F. et al. O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer 68, 484-490 (2010).
46. Gomez-Roca, C. et al. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J.Thorac. Oncol. 4, 1212-1220 (2009).
47. Mehrotra, J. et al. Very high frequency of hypermethylated genes in breast cancer metastasis to bone, brain and lung. Clin. Cancer Res. 10, 3104-3109 (2004). (Pubitemid 38619690)
48. Ding, L. et al. Genome remodeling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
49. Stark, A., Tongers, K., Maass, N., Mehdom, H. & Held-Feidt, J. Reduced metastasis suppressor gene mRNA expression in breast cancer brain metastases. J.Cancer Res. Clin. Oncol. 131, 191-198 (2005). (Pubitemid 40175014)
50. Stark, A. et al. Reduced mRNA and protein expression of BCL-2 versus decreased mRNA and increased protein expression of BAX in breast cancer brain metastases: a real-time PCR and immunohistochemical evaluation. Nuerological Res. 28, 787-793 (2006). (Pubitemid 44904449)
51. Veenendaal, L. et al. Differential notch and TGFβ signaling in primary colorectal tumors and their corresponding metastases. Cell. Oncol. 30, 1-11 (2008). (Pubitemid 351161033)
52. Palmieri, D. et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol. Cancer Res. 7, 1438-1445 (2009).
53. Xie, T.X. et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 66, 3188-3196 (2006).
54. Palmieri, D. et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 67, 4190-4198 (2007). (Pubitemid 46815065)
55. Navab, R. et al. Cooverexpression of Met and Hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 11, 1292-1300 (2009).
56. Nguyen, D. et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51-62 (2009).
57. Zhang, L., Sullivan, P., Goodman, J., Gunaratne, P. & Marchetti, D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 71, 645-654 (2011).
58. Cocconi, G. et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest. 8, 327-334 (1990). (Pubitemid 20352764)
59. Boogerd, W., Dalesio, O., Bais, E. M. & van der Sande, J. J. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 69, 972-980 (1992).
60. Rosner, D., Nemoto, T. & Lane, W. W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58, 832-839 (1986). (Pubitemid 16035278)
61. Oberhoff, C. et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 24, 256-260 (2001). (Pubitemid 32664555)
62. Kurt, M., Aksoy, S., Hayran, M. & Guler, N. A retrospective review of breast cancer patients with central nervous system metastases treated with capecitabine. J.Clin. Oncol. Abstr. 25, 1098 (2007).
63. Lin, N. et al. PhaseII trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J.Clin. Oncol. Abstr. 24, 503 (2006).
64. Lin, N. et al. Multicenter PhaseII study of lapatinib in patients with brain metastases from HER-2 positive breast cancer. Clin. Cancer Res. 15, 1452-1459 (2009).
65. Quirt, I. et al. Temozolomide for the treatment of metastatic melanoma. Curr. Oncol. 14, 27-33 (2007).
66. Ekenel, M., Hormigo, A., Peak, S., DeAngelis, L. & Abrey, L. Capecitabine therapy of central nervous system metastases from breast cancer. J.Neurooncol. 85, 223-227 (2007). (Pubitemid 47629405)
67. Rivera, E. et al. PhaseI study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases of breast cancer. Cancer 107, 1348-1354 (2006). (Pubitemid 44452785)
68. Mehta, M. et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J.Neurooncol. 96, 71-83 (2010).
69. Ceresoli, G. et al. Gefitinib in patients with brain metastases from non-small cell lung cancer: a prospective trial. Ann. Oncol. 15, 1042-1047 (2004). (Pubitemid 39089780)
70. Wu, C. et al. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 57, 359-364 (2007). (Pubitemid 47285416)
71. Togashi, Y. et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J.Thorac. Oncol. 5, 950-955 (2010).
72. Omuro, A.M. et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103, 2344-2348 (2005). (Pubitemid 40686581)
73. Bria, E. et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res. Treat. 109, 231-239 (2008). (Pubitemid 351644860)
74. Stemmler, H.J. et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of the blood-brain barrier. Anticancer Drugs 18, 23-28 (2007).
75. Polli, J. et al. The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}6-[5-({[2-(methylsulfonyl)ethyl]amino} methyl)2-furyl]4-quinazolinamine (GWS572016, Lapatinib) disposition and drug interactions. Drug Metab. Dispos. 36, 695-701 (2008). (Pubitemid 351468376)
76. Lien, E. A., Wester, K., Lønning, P. E., Solheim, E. & Ueland, P. M. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br. J.Cancer 63, 641-645 (1991).
77. Socinski, M. et al. Safety of bevicizumab in patients with non-small-cell lung cancer and brain metastases. J.Clin. Oncol. 27, 5255-5261 (2009).
78. Stadler, W. et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in north America. Cancer 116, 1272-1280 (2010).
79. Pajouhesh, H. & Lenz, G.R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2, 541-553 (2005). (Pubitemid 41393264)
80. Ohtsuki, S. & Terasaki, T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res. 24, 1745-1758 (2007). (Pubitemid 47206624)
81. Szakacs, G., Paterson, J., Ludwig, J., Booth-Genthe, C. & Gottesman, M. Targeting multidrug resistance in cancer. Nature Rev. Drug Discov. 5, 219-234 (2006). (Pubitemid 43336035)
82. Noguchi, K., Katayama, K., Mitsuhashi, J. & Sugimoto, Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv. Drug Deliv. Rev. 61, 26-33 (2009).
83. Lagas, J. et al. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol. Cancer Ther. 9, 319-326 (2010).
84. Agarwal, S., Sane, R., Gallardo, J. L., Ohlfest, J. R. & Elmquist, W. F. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J.Pharmacol. Exp. Ther. 334, 147-155 (2010).
85. Armulik, A. et al. Pericytes regulate the blood-brain barrier. Nature 468, 557-561 (2010).
86. Daneman, R., Zhou, L., Kebede, A. A. & Barres, B. A. Ericytes are required for blood-brain barrier integrity during embryogenesis. Nature 468, 562-566 (2010).
87. Ahmad, A., Gassmann, M. & Ogunshola, O. Maintaining blood-brain barrier integrity: pericytes perform better than astrocytes during prolonged oxygen deprivation. J.Cell. Physiol. 218, 612-622 (2009).
88. Palmieri, D. et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer. Clin. Cancer Res. 15, 6148-6157 (2009).
89. Luu, T. et al. A PhaseII trial of vorinostat (Suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin. Cancer Res. 14, 7138-7142 (2008).
90. Ramalingam, S. et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J.Clin. Oncol. 28, 56-62 (2010).
91. Baschnagel, A. et al. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown invitro and as intracranial xenografts. Mol. Cancer Ther. 8, 1589-1595 (2009).
92. Gril, B. et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J.Natl. Cancer Inst. 100, 1092-1103 (2008).
93. Emanuel, S. et al. Cellular and invivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol. Pharmacol. 73, 338-348 (2008). (Pubitemid 351159204)
94. Kong, L.-Y. et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficaceous against established central nervous system melanoma and inhibits regulatory Tcells. Clin. Cancer Res. 14, 5759-5768 (2008).
95. Hoffmann, J. et al. Sagopilone crosses the blood-brain barrier invivo to inhibit brain tumor growth and metastases. Neurooncology 11, 158-166 (2008).
96. Ozduman, K., Wollman, G., Piepmeier, J. & van den Pol, A. N. Systemic vesicular stomatitus virus selectively destroys multifocal glioma and metastatic carcinoma in the brain. J.Neursci. 28, 1882-1893 (2008). (Pubitemid 351302677)
97. Yang, W. et al. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Therapy 11, 1579-1590 (2004).
98. Massard, C. et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann. Oncol. 21, 1027-1031 (2010).
99. Cameron, D. et al. A PhaseIII randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 112, 533-543 (2008).
100. Heon, S. et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefintib or erlotinib. Clin. Cancer Res. 16, 5873-5882 (2010).
101. Grinberg-Rashi, H. et al. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin. Cancer Res. 15, 1755-1761 (2009).
102. Grasslin, O. et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J.Clin. Oncol. 28, 2032-2037 (2010).
103. Sperduto, P. et al. A graded prosnostic assessment (GPA) for women with breast cancer and brain metastasssses. J.Clin. Oncol. Suppl. Abstr. 28 1028 (2010).
104. Thomas, F. et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 26, 2486-2494 (2009).
105. Hu, J. et al. Phosphodiesterase type 5 inhibitors increase herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS ONE 5, e10108 (2010).
106. Yuan, H. et al. Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int. J.Radiat. Oncol. Biol. Phys. 66, 860-866 (2006). (Pubitemid 44436715)
107. Muldoon, L. et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J.Clin. Oncol. 16, 2295-2305 (2007). (Pubitemid 46954658)
108. Rosenberg, A. & Knox, S. Radiation sensitization with redox modulators: a promising approach. Int. J.Radiat. Oncol. Biol. Phys. 64, 343-354 (2006). (Pubitemid 43083418)
109. Francis, D., Richards, G., Forouzannia, A., Mehta, M. & Kuntia, D. Motexafin gadolinium: a novel radiosensitizer for brain tumors. Expert Opin. Pharmacother. 10, 2171-2180 (2009).
110. Russo, A. et al. Invitro and invivo radiosensitization of glioblastoma cells by the poly (ADP-Ribose) polymerase inhibitor E7016. Clin. Cancer Res. 15, 607-612 (2009).
111. Morgan, M. et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70, 4972-4981 (2010).
112. Gerster, K. et al. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. Int. J.Radiat. Oncol. Biol. Phys. 77, 253-260 (2010).
113. Chung, E. et al. Invitro and invivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin. Cancer Res. 15, 3050-3057 (2009).
114. Camphausen, K. et al. Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression. Cancer Res. 65, 10389-10393 (2005). (Pubitemid 41743732)
115. Chang, E. et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomized controlled trial. Lancet Oncol. 10, 1037-1044 (2009).
116. Zhao, W. & Robbins, M. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr. Med. Chem. 16, 130-143 (2009).
117. Fukuda, H. et al. Irradiation-induced progenitor cell death in the developing brain is resistant to erythropoietin treatment and caspase inhibition. Cell Death Differ. 11, 1166-1178 (2004). (Pubitemid 39529959)
118. Limoli, C. et al. Cell-density-dependent regulation of neural precursor cells function. Proc. Natl Acad. Sci. USA 101, 16052-16057 (2004). (Pubitemid 39507925)
119. Mildenberger, M., Beach, T., McGeer, E. & Ludgate, C. An animal model of prophylactic cranial irradiation: histologic effects at acute, early and delayed stages. Int. J.Radiat. Oncol. Biol. Phys. 18, 1051-1060 (1990). (Pubitemid 20182337)
120. Monje, M., Toda, H. & Palmer, T. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302, 1760-1765 (2003). (Pubitemid 37505739)
121. Schindler, M., Forbes, M., Robbins, M. & Riddle, D. Aging-dependent changes in the radiation response of the adult rat brain. Int. J.Radiat. Oncol. Biol. Phys. 70, 826-834 (2008).
122. Khuntia, D., Brown, P., Li, J. & Mehta, M. Whole-brain radiotherapy in the management of brain metastasis. J.Clin. Oncol. 24, 1295-1304 (2006). (Pubitemid 46622033)
123. Robbins, M. et al. The AT1 receptor antagonist, L-158, 809, prevents or ameliorates factionated whole-brain irradiation-induced cognitive impairment. Int. J.Radiat. Oncol. Biol. Phys. 73, 499-505 (2009).
124. Clar, C., Royle, P. & Waugh, N. Adding piaglitazone to insulin containing regimens in type2 diabetes: systematic review and meta-analysis. PLoS ONE 4, e6112 (2009).
125. Abourbih, S. et al. Effect of bibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am. J.Med. 122, 962e1-962e8 (2009).
126. Zhao, W. et al. Administration of the peroxisomal proliferator-activated receptor (PPAR)g pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impariment. Int. J.Radiat. Oncol. Biol. Phys. 67, 6-9 (2007). (Pubitemid 44959517)
127. Ramanan, S. et al. The PPARα agonist fenobibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain radiation. Int. J.Radiat. Oncol. Biol. Phys. 75, 870-877 (2009).
128. Atwood, T. et al. Quantitative magnetic resonance spectroscopy reveals a potential relationship between radiation-induced changes in rat brain metabolites and cognitive impairment. Radiat. Res. 168, 574-581 (2007). (Pubitemid 351295121)
129. Kim, K. et al. High-throughput screening identifies two classes of antibiotics as radioprotectors: tetracyclines and fluoroquinolones. Clin. Cancer Res. 15, 7238-7245 (2009).
130. Gleissner, B. & Chamberlain, M. Neoplastic meningitis. Lancet Neurol. 5, 443-451 (2006).
131. Pedersen, P.H. et al. Leptomeningeal tissue: a barrier against brain tumor cell invasion. J.Natl Cancer Inst. 86, 1593-1599 (1994).
132. Herrlinger, U. et al. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J.Neurol. Sci. 223, 167-178 (2004). (Pubitemid 39164359)
133. Kesari, S. & Batchelor, T. Leptomeningeal metastases. Neurol. Clin. 21, 25-66 (2003). (Pubitemid 36169344)
134. Borgelt, B. et al. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int. J.Radiat. Oncol. Biol. Phys. 7, 1633-1638 (1981). (Pubitemid 12212604)
135. Borgelt, B. et al. The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int. J.Radiat. Oncol. Biol. Phys. 6, 1-9 (1980). (Pubitemid 10103009)
136. Patil, C. G., Pricola, K., Garg, S. K., Bryant, A. & Black, K. L. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst. Rev. CD006121 (2010).
137. Kalkanis, S. et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J.Neurooncol. 96, 33-44 (2010).
138. Slotman, B. et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. New Engl. J.Med. 357, 664-672 (2007). (Pubitemid 47267236)
139. Lester, J., MacBeth, F. & Coles, B. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: a Cochrane review. Int. J.Radiat. Oncol. Biol. Phys. 63, 690-694 (2005). (Pubitemid 41400053)
140. Sanghavi, S. et al. Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by RTOG recursive partitioning analysis method. Int. J.Radiat. Oncol. Biol. Phys. 51, 426-434 (2001). (Pubitemid 32884288)
141. Petrovich, Z., Yu, C., Giannotta, S. L., O'Day, S. & Apuzzo, M. L. Survival and pattern of failure in brain metastasis treated with stereotactic γ knife radiosurgery. J.Neurosurg. 97, 499-506 (2002). (Pubitemid 35424334)
142. Folkman, J. & Camphausen, K. What does radiotherapy do to endothelial cells? Science 293, 227-228 (2001). (Pubitemid 32694723)